



Curriculum Vitae

Personal information **Anna Maria Urbaniak**

Work experience

1. Employer: Norwegian Medicines Agency
 - Start date: 022017
 - End date:
 - Position: Statistical Assessor
 - Activities: HTA assessor
 - Country: Norway
2. Employer: Boehringer Ingelheim
 - Start date: 102012
 - End date: 102015
 - Position: Associate Pricing Manager
 - Activities: pricing and reimbursement of pharmaceuticals, patient access schemes
 - Country: United Kingdom
3. Employer: GfK Market Access
 - Start date: 042012
 - End date: 102012
 - Position: Senior Analyst, healthcare
 - Activities:
 - Country: United Kingdom
4. Employer: GfK Market Access
 - Start date: 052011
 - End date: 032012
 - Position: Analyst, healthcare
 - Activities:
 - Country: United Kingdom

Education and training

1. Subject: Norwegian Medicines Agency
 - Start date: 082016
 - End date: 122016
 - Qualification: Internship / Department of Pharmacoeconomics
 - Organisation: statistical analysis of real world data from the Norwegian Prescription Database (NorPD)
 - Country: Norway
2. Subject: City, University of London
 - Start date: 092014
 - End date: 122016
 - Qualification: Master of Science (MSc) in Economic Evaluation in Healthcare
 - Organisation: statistics, advanced economic evaluation, health economics and modelling, welfare economics and epidemiology
 - Country: United Kingdom
3. Subject: Imperial College London
 - Start date: 092007
 - End date: 042011
 - Qualification: Doctor of Philosophy (PhD) in Clinical Medicine Research
 - Organisation: immunology, molecular biology, genetics
 - Country: United Kingdom
4. Subject: University of Ulster
 - Start date: 092006
 - End date: 102007
 - Qualification: Master of Research (MRes), Biomedical Sciences
 - Organisation:
 - Country: United Kingdom
5. Subject: University of Gdansk and the Medical University of Gdansk
 - Start date: 092003
 - End date: 062006
 - Qualification: Bachelor of Science (BSc), Biotechnology
 - Organisation:
 - Country: Poland

Additional information

Publications

Ali S, Kjekken R, Niederlaender C, Markey G, Saunders TS, Opsata M, Moltu K, Bremnes B, Grønevik E, Muusse M, Håkonsen GD, Skibeli V, Kalland ME, Wang I, Buajordet I, Urbaniak A, Johnston J, Rantell K, Kerwash E, Schuessler_Lenz M, Salmonson T, Bergh J, Gisselbrecht C, Tzogani K, Papadouli I, Pignatti F. The European Medicines Agency Review of Kymriah (Tisagenlecleucel) for the Treatment of Acute Lymphoblastic Leukemia and Diffuse Large B-Cell Lymphoma. *Oncologist*. 2019 Oct 16. Page TH, Urbaniak AM, Espirito Santo AI, Danks L, Smallie T, Williams LM, Horwood NJ. Bruton's tyrosine kinase regulates TLR7/8-induced TNF transcription via nuclear factor- κ B recruitment. *Biochem Biophys Res Commun*. 2018 May 5;499(2):260-266. doi: 10.1016/j.bbrc.2018.03.140. Epub 2018 Mar 22. Urbaniak AM, Strøm BO, Krøntveit R, Svanqvist KH. Prescription Patterns of Non-Vitamin K Oral Anticoagulants Across Indications and Factors Associated with Their Increased

Prescribing in Atrial Fibrillation Between 2012_2015: A Study from the Norwegian Prescription Database. *Drugs Aging*. 2017 Aug;34(8):635_645. doi: 10.1007/s40266_017_0476_4. Schoenherr N., Watkins M., Urbaniak AM. The UK Cancer Drug Fund Scoring System and the Impact of the Incremental Cost Effectiveness Ratio on Funding Decisions. *Value Health*. 2014 Nov;17(7):A657 Horwood NJ., Urbaniak AM., Danks L. Tec family kinases in inflammation and disease. *Int Rev Immunol*. 2012 Apr;31(2):87_103. Smolinska MJ., Page TH., Urbaniak AM., Mutch BE., Horwood NJ. Hck tyrosine kinase regulates TLR4_induced TNF and IL_6 production via AP_1. *J Immunol*. 2011 Dec 1;187(11):6043_51. Foxwell BMJ., Urbaniak AM., Gillespie J., Smolinska M., Page TH. Tyrosine kinases and inflammatory signalling. *Curr Mol Med*. 2009 Feb;9(1):69_85. Review.

[Projects](#)

[Memberships](#)

[Other Relevant Information](#)